Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

EP: 1.The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System

EP: 2.Recent Insights into the Pathophysiology of Alzheimer Disease

EP: 3.Genetic Aspects of Alzheimer Disease

EP: 4.The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease

EP: 5.Potential Consequences of Early Diagnosis of Alzheimer Disease

EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing

EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease

Now Viewing

EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

EP: 9.Clinical Decision-Making for Alzheimer Disease Management

EP: 10.Cost, Value, and Affordability of Treatment for Alzheimer Disease

EP: 11.Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

EP: 12.Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

EP: 13.Payer Coverage Considerations for New Treatments for Alzheimer Disease

EP: 14.Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

Video content above is prompted by the following question(s):

• What has been the clinical impact and the target patients for the use of anti-amyloid β monoclonal antibodies?
  • Aducanumab approved by the FDA in 2021; development and commercialization discontinued on Jan 31, 2024
  • Lecanemab approved by the FDA in 2023